Access to Care for Multiple Sclerosis in Times of Economic Crisis in Greece – the HOPE II Study

Background While there is currently no cure for multiple sclerosis (MS), treatment with biologic diseasemodifying drugs (bDMDs) can reduce the impact of the condition on the lives of patients. In Greece, the regulatory change in the distribution system of bDMDs, limited their administration throug...

Full description

Bibliographic Details
Main Authors: Kyriakos Souliotis, Elena Alexopoulou, Manto Papageorgiou, Anastasia Politi, Panagiota Litsa, Xenophon Contiades
Format: Article
Language:English
Published: Kerman University of Medical Sciences 2016-02-01
Series:International Journal of Health Policy and Management
Subjects:
Online Access:http://www.ijhpm.com/pdf_3100_4e429ed61f7b5cd9ba6aee079bb957e0.html
_version_ 1818414286272200704
author Kyriakos Souliotis
Elena Alexopoulou
Manto Papageorgiou
Anastasia Politi
Panagiota Litsa
Xenophon Contiades
author_facet Kyriakos Souliotis
Elena Alexopoulou
Manto Papageorgiou
Anastasia Politi
Panagiota Litsa
Xenophon Contiades
author_sort Kyriakos Souliotis
collection DOAJ
description Background While there is currently no cure for multiple sclerosis (MS), treatment with biologic diseasemodifying drugs (bDMDs) can reduce the impact of the condition on the lives of patients. In Greece, the regulatory change in the distribution system of bDMDs, limited their administration through the designated pharmacies of the National Organization for Healthcare Services Provision (EOPYY) or the National Health System (ESY) hospitals, thus potentially impacting access to MS treatment. In this context, the aim of this paper was to assess the barriers to bDMDs, by recording MS patients’ experiences. Methods A survey research was conducted between January and February 2014 in Athens and 5 other major Greek cities with the methods of personal and telephone interview. A structured questionnaire was used to elicit socio-economic and medical information, information related to obstacles in accessing bDMDs and medical treatment, from MS patients that visited EOPYY pharmacies during the study period. Results During the last year 69% of 179 participants reported that the distribution system of bDMDs has improved. Thirteen percent of participants encountered problems in accessing their medication, and 16.9% of participants in accessing their physician, with the obstacles being more pronounced for non-Athens residents. Frequent obstacles to bDMDs were the distance from EOPYY pharmacies and difficulties in obtaining a diagnosis from an EOPYY/ESY physician, while obstacles to medical care were delays in appointment booking and travel difficulties. Conclusion Even though the major weaknesses of the distribution system of bDMDs have improved, further amelioration of the system could be achieved through the home delivery of medicines to patients living in remote areas, and through the development of a national MS registry.
first_indexed 2024-12-14T11:16:41Z
format Article
id doaj.art-83c022d1447741b28a77e1d048d68819
institution Directory Open Access Journal
issn 2322-5939
2322-5939
language English
last_indexed 2024-12-14T11:16:41Z
publishDate 2016-02-01
publisher Kerman University of Medical Sciences
record_format Article
series International Journal of Health Policy and Management
spelling doaj.art-83c022d1447741b28a77e1d048d688192022-12-21T23:03:58ZengKerman University of Medical SciencesInternational Journal of Health Policy and Management2322-59392322-59392016-02-0152838910.15171/ijhpm.2015.173Access to Care for Multiple Sclerosis in Times of Economic Crisis in Greece – the HOPE II StudyKyriakos Souliotis0Elena Alexopoulou1Manto Papageorgiou2Anastasia Politi3Panagiota Litsa4Xenophon Contiades5Faculty of Social and Political Sciences, University of Peloponnese, Corinth, Greece; Centre for Health Services Research, Medical School, University of Athens, Athens, GreeceFaculty of Social Sciences, University of Peloponnese, Corinth, Greece; National Organization for Healthcare Services Provision, Athens, GreeceFaculty of Social Sciences, University of Peloponnese, Corinth, GreeceDepartment of Statistics, Athens University of Economics and Business, Athens, GreeceCentre for Health Services Research, Medical School, University of Athens, Athens, GreeceFaculty of Social Sciences, University of Peloponnese, Corinth, GreeceBackground While there is currently no cure for multiple sclerosis (MS), treatment with biologic diseasemodifying drugs (bDMDs) can reduce the impact of the condition on the lives of patients. In Greece, the regulatory change in the distribution system of bDMDs, limited their administration through the designated pharmacies of the National Organization for Healthcare Services Provision (EOPYY) or the National Health System (ESY) hospitals, thus potentially impacting access to MS treatment. In this context, the aim of this paper was to assess the barriers to bDMDs, by recording MS patients’ experiences. Methods A survey research was conducted between January and February 2014 in Athens and 5 other major Greek cities with the methods of personal and telephone interview. A structured questionnaire was used to elicit socio-economic and medical information, information related to obstacles in accessing bDMDs and medical treatment, from MS patients that visited EOPYY pharmacies during the study period. Results During the last year 69% of 179 participants reported that the distribution system of bDMDs has improved. Thirteen percent of participants encountered problems in accessing their medication, and 16.9% of participants in accessing their physician, with the obstacles being more pronounced for non-Athens residents. Frequent obstacles to bDMDs were the distance from EOPYY pharmacies and difficulties in obtaining a diagnosis from an EOPYY/ESY physician, while obstacles to medical care were delays in appointment booking and travel difficulties. Conclusion Even though the major weaknesses of the distribution system of bDMDs have improved, further amelioration of the system could be achieved through the home delivery of medicines to patients living in remote areas, and through the development of a national MS registry.http://www.ijhpm.com/pdf_3100_4e429ed61f7b5cd9ba6aee079bb957e0.htmlMultiple Sclerosis (MS)Patient AccessBiologicsPharmaceutical PolicyRecessionGreece
spellingShingle Kyriakos Souliotis
Elena Alexopoulou
Manto Papageorgiou
Anastasia Politi
Panagiota Litsa
Xenophon Contiades
Access to Care for Multiple Sclerosis in Times of Economic Crisis in Greece – the HOPE II Study
International Journal of Health Policy and Management
Multiple Sclerosis (MS)
Patient Access
Biologics
Pharmaceutical Policy
Recession
Greece
title Access to Care for Multiple Sclerosis in Times of Economic Crisis in Greece – the HOPE II Study
title_full Access to Care for Multiple Sclerosis in Times of Economic Crisis in Greece – the HOPE II Study
title_fullStr Access to Care for Multiple Sclerosis in Times of Economic Crisis in Greece – the HOPE II Study
title_full_unstemmed Access to Care for Multiple Sclerosis in Times of Economic Crisis in Greece – the HOPE II Study
title_short Access to Care for Multiple Sclerosis in Times of Economic Crisis in Greece – the HOPE II Study
title_sort access to care for multiple sclerosis in times of economic crisis in greece the hope ii study
topic Multiple Sclerosis (MS)
Patient Access
Biologics
Pharmaceutical Policy
Recession
Greece
url http://www.ijhpm.com/pdf_3100_4e429ed61f7b5cd9ba6aee079bb957e0.html
work_keys_str_mv AT kyriakossouliotis accesstocareformultiplesclerosisintimesofeconomiccrisisingreecethehopeiistudy
AT elenaalexopoulou accesstocareformultiplesclerosisintimesofeconomiccrisisingreecethehopeiistudy
AT mantopapageorgiou accesstocareformultiplesclerosisintimesofeconomiccrisisingreecethehopeiistudy
AT anastasiapoliti accesstocareformultiplesclerosisintimesofeconomiccrisisingreecethehopeiistudy
AT panagiotalitsa accesstocareformultiplesclerosisintimesofeconomiccrisisingreecethehopeiistudy
AT xenophoncontiades accesstocareformultiplesclerosisintimesofeconomiccrisisingreecethehopeiistudy